Telix Pharmaceuticals Ltd — Director's Dealing 2026

Mar 17, 2026

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Telix Pharmaceuticals Limited ABN 85 616 620 369

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Christian Behrenbruch
Date of last notice	7 November 2025

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct interest
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.	N/A
Date of change	16 March 2026
No. of securities held prior to change	Direct Interest•553,298 fully paid ordinary shares (including400,000 American Depository Shares (eachrepresenting 1 ordinary share) in TelixPharmaceuticals Limited).•100,708 share options with an exercise price of$4.38 per option and an expiry date of 26January 2026. Options vest upon achievementof $100M in cumulative revenue from productsales. Options allotted following shareholderapproval at the AGM held 12 May 2021(TLXO009 - TLXAL).•93,114 Performance Share Appreciation Rights(PSARs) (notional exercise price $4.95) (TLXO012- TLXAO) issued following shareholder approvalat the AGM held 18 May 2022.

See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

	•120,268 PSARs (notional exercise price $6.90)(TLXO015 - TLXAO) issued following shareholderapproval at the AGM held 24 May 2023.•144,037 PSARs (notional exercise price $11.94)(TLXO024 - TLXAO) issued following shareholderapproval at the AGM held 22 May 2024.•166,483 PSARs (notional exercise price $28.67)(TLXO030 - TLXAO) issued following shareholderapproval at the AGM held 21 May 2025.•2,595 Share Rights (SRs) (Nil exercise price)(TLXO031 - TLXAU) issued following shareholderapproval at the AGM held 21 May 2025.Indirect interest•20,675,000 fully paid ordinary shares (Elk RiverHoldings Pty Ltd as Trustee for The BehrenbruchFamily Trust).
Class	Performance Share Appreciation Rights (TLXO015 –TLXAO)
Number acquired	Nil
Number disposed	20,045
Value/ConsiderationNote: If consideration is non-cash, provide details and estimatedvaluation	Nil
No. of securities held after change	Direct Interest•654,006 fully paid ordinary shares (including400,000 American Depository Shares (eachrepresenting 1 ordinary share) in TelixPharmaceuticals Limited).•93,114 PSARs (notional exercise price $4.95)(TLXO012 - TLXAO) issued following shareholderapproval at the AGM held 18 May 2022.•100,223 PSARs (notional exercise price $6.90)(TLXO015 - TLXAO) issued following shareholderapproval at the AGM held 24 May 2023.•144,037 PSARs (notional exercise price $11.94)(TLXO024 - TLXAO) issued following shareholderapproval at the AGM held 22 May 2024.•166,483 PSARs (notional exercise price $28.67)(TLXO030 - TLXAO) issued following shareholderapproval at the AGM held 21 May 2025.•2,595 SRs (Nil exercise price) (TLXO031 - TLXAU)issued following shareholder approval at theAGM held 21 May 2025.Indirect interest•20,675,000 fully paid ordinary shares (Elk RiverHoldings Pty Ltd as Trustee for The BehrenbruchFamily Trust).

See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 2

Appendix 3Y Change of Director’s Interest Notice

		Nature of change	Nature of change	Nature of change	120,268 PSARs (TLXO015 – TLXAO) were granted toDr Behrenbruch at the maximum possible outcomeof 150% of target following shareholder approval atthe AGM held 24 May 2023. At testing, following theconclusion of the performance period, the Boardapproved a vesting outcome of 125% of target(100,223 PSARs with an expiry date of two yearsfrom vesting), with the remaining 25% lapsed(20,045 PSARs). Refer to the Remuneration reportwithin Telix's 2025 Annual report athttps://ir.telixpharma.com/financial-information/annual-reports	120,268 PSARs (TLXO015 – TLXAO) were granted toDr Behrenbruch at the maximum possible outcomeof 150% of target following shareholder approval atthe AGM held 24 May 2023. At testing, following theconclusion of the performance period, the Boardapproved a vesting outcome of 125% of target(100,223 PSARs with an expiry date of two yearsfrom vesting), with the remaining 25% lapsed(20,045 PSARs). Refer to the Remuneration reportwithin Telix's 2025 Annual report athttps://ir.telixpharma.com/financial-information/annual-reports	120,268 PSARs (TLXO015 – TLXAO) were granted toDr Behrenbruch at the maximum possible outcomeof 150% of target following shareholder approval atthe AGM held 24 May 2023. At testing, following theconclusion of the performance period, the Boardapproved a vesting outcome of 125% of target(100,223 PSARs with an expiry date of two yearsfrom vesting), with the remaining 25% lapsed(20,045 PSARs). Refer to the Remuneration reportwithin Telix's 2025 Annual report athttps://ir.telixpharma.com/financial-information/annual-reports
		Example: on-market trade, off-market trof securities under dividend reinvestmeback	ade, exercise of options,nt plan, participation in	issuebuy-	Dr Behrenof 150% ofthe AGM h	ruch at the maxitarget following seld 24 May 2023.	mum possible outhareholder apprAt testing, follow
					conclusion	of the performan	ce period, the Bo
					approved a(100223 P	vesting outcomeSARs with an expi	of 125% of targery date of two ye
					,from vestin	g), with the rema	ining 25% lapsed
					(20,045 PS	ARs). Refer to the'	Remuneration re
					within Telihttps://irt	xs 2025 Annual reelixpharmacom/f	port atinancial-
					.informatio	.n/annual-reports
Part 2 – Change of director’s			interests in contr	acts
Note: In the case of a company, interestsdisclosed in this part.			which come within parag	raph (ii) of the definition		of “notifiable interest of	a director” should be

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interestrelated prior to changeNote: Details are only required for a contract in relation to which theinterest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide details and an estimatedvaluation	N/A
Interest after change	N/A

3 –[+] Closed period Part

Were the interests in the securities or contractsdetailed above traded during a+closed periodwhere prior written clearance was required?	No
If so, was prior written clearance provided toallow the trade to proceed during this period?	N/A
If prior written clearance was provided, on whatdate was this provided?	N/A

See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 3